FDA holding meetings with industry to gather input on reengineering program.
This article was originally published in The Gray Sheet
Executive SummaryMEDICAL DEVICE REPORTING ABOLITION SUGGESTED BY HIMA MEMBERS at a recent meeting with Center for Devices and Radiological Health topsiders. According to FDA minutes of an April 11 session held at the Health Industry Manufacturers Association headquarters to discuss CDRH reengineering, manufacturers suggested that if FDA cannot establish the usefulness of MDR in protecting public health, it should abolish the program and regulations like MDR and use its staff elsewhere.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.